Investigator Alex Diederichsen, PhD recaps the results of DANCAVAS trial, which found that after more than 5 years, the invitation to undergo comprehensive cardiovascular screening and treatment if detected did not significantly reduce the incidence of death from any cause among men 65 to 74 years of age.
Related posts:
